Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.


TSX:EDT - Post by User

Comment by TechOneon Nov 07, 2025 8:34pm
113 Views
Post# 36778985

RE:RE:RE:RE:RE:RE:RE:New Press Release - Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

RE:RE:RE:RE:RE:RE:RE:New Press Release - Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateMost interesting thing for me was the comment that the company was in interactive discussions with FDA. Presumably, this should result in a better and more effective submission. 

So I guess we wait for a month for clarification and more meat. Not that we have much choice in the process or progress. 

We will have to take their word that none of this will have any impact on the time lines for the rollout. 
<< Previous
Bullboard Posts
Next >>